Business Context and Reporting Period
This Form 8-K was filed by Stellar Biotechnologies, Inc. on December 7, 2016, reporting events occurring on December 1, 2016. The registrant is incorporated in British Columbia, Canada, with principal executive offices in Port Hueneme, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
- Executive Appointment: Dr. Gregory T. Baxter was appointed as Executive Vice President of Corporate Development, effective December 1, 2016.
- Board Resignation: Simultaneously with his appointment to the management team, Dr. Baxter resigned from his position as an independent member of the Board of Directors, effective immediately on December 1, 2016.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. The document serves solely to disclose the change in officer and director status.
Investor Verification Checklist
- Confirm the effective date of Dr. Baxter's transition from Board member to Executive Vice President.
- Verify if Dr. Baxter's resignation from the Board impacts the composition of any board committees.
- Review the October 24, 2016 Form 8-K referenced in the text for prior details on this appointment.